Why Keeping The End in Mind is Critical for Every Medtech Entrepreneur: Interview with Erica Rogers, CEO of Silk Road Medical

In this two-part interview, I was lucky enough to sit down with
Erica Rogers, CEO of Silk Road Medical. We first spoke a few
years ago and then again much more recently to catch up on what
had changed at Silk Road since our first conversation.


During our catch up, we discussed how Erica led her team at Silk
Road through PMA approval, successful insurance coverage and
reimbursement strategy, which led to a very rewarding public
offering for Silk Road, opening at $20 a share. This resulted in
the opportunity to continue the company’s goal, which is to
change the standard of care in carotid artery disease with their
TCAR procedure.


Much of our first conversation was about Erica’s career
trajectory and how she was able to successfully, and gracefully,
exit multiple medtech companies. Her lengthy career and insight
as a medtech thought leader is just as interesting today as it
was when we recorded our conversation.


Before leading Silk Road, Erica was the COO of Medicines360, a
nonprofit pharmaceutical company developing drugs and devices for
women. Erica was the founder and CEO of Allux Medical as well as
the cofounder of Visiogen, which was acquired by Abbott Medical
Optics in 2009.


Prior to that, Erica spent over 12 years at Boston Scientific in
a variety of sales and marketing positions. She began her career
in pharmaceutical sales after receiving a B.S. in Zoology from
San Diego State University. Erica holds five issued and 15
pending US patents for medical devices in nanotechnology.

See more...